# China NMPA Drug Inspection - Yongzhou Yongdian Traditional Chinese Medicine Pieces Co., Ltd. - Mulberry

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/yongzhou-yongdian-traditional-chinese-medicine-pieces-co-ltd/f554e7d6-84ac-467c-b3cc-f2c08b6cc556/
Source feed: China

> China NMPA drug inspection for Yongzhou Yongdian Traditional Chinese Medicine Pieces Co., Ltd. published November 28, 2017. Drug: Mulberry. The Henan Provincial Food and Drug Administration announced on November 28, 2017, findings from quality testing that rev

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Henan Provincial Food and Drug Administration Regarding 4 Batches of Substandard Drugs Found in Spot Checks
- Company Name: Yongzhou Yongdian Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2017-11-28
- Drug Name: Mulberry
- Inspection Finding: Properties are not up to standard
- Action Taken: Risk control measures such as sealing, seizing, and suspending sales will be implemented, and cases will be investigated and dealt with in accordance with the law.
- Summary: The Henan Provincial Food and Drug Administration announced on November 28, 2017, findings from quality testing that revealed four batches of drugs were substandard. This regulatory action, part of routine supervision, highlighted significant quality control issues across several pharmaceutical companies. Yuzhou Baicaohui Pharmaceutical Co., Ltd. produced substandard Agarwood (batch 160522). Yuzhou Jindi Traditional Chinese Medicine Pieces Co., Ltd.'s Mulberry mistletoe (batch 151101) failed quality tests due to appearance issues. Luoyang Kangxin Traditional Chinese Medicine Pieces Co., Ltd. manufactured Safflower (batch 170101) which exhibited substandard acid-insoluble ash content. Critically, Henan Shennong Pharmaceutical Co., Ltd.'s Qingkailing Injection (batch 16100201) was found to contain visible foreign matter. In response to these violations, the Henan Provincial Food and Drug Administration mandated prompt risk control measures. These included sealing, seizing, and suspending the sale of the non-compliant drug batches. Additionally, the regulatory body instructed relevant departments to conduct investigations and impose legal penalties on the responsible entities, ensuring compliance with established pharmaceutical quality standards.

Company: https://www.globalkeysolutions.net/companies/yongzhou-yongdian-traditional-chinese-medicine-pieces-co-ltd/37fbef04-6474-4ae0-aa86-9528b442e463/